February 15, 2019
Kowa will restructure its pharmaceutical business segment in April, including its ethical drug business, being currently overseen by its subsidiaries. Under the move, Kowa on April 1 will merge its subsidiaries Kowa Pharmaceutical and Kowa Shinyaku, which are engaged in...read more